Iacopo Olivotto

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8019781/iacopo-olivotto-publications-by-year.pdf
Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296 papers	15,234 citations	58 h-index	118 g-index
367 ext. papers	19,222 ext. citations	6.2 avg, IF	6.13 L-index

#	Paper	IF	Citations
296	Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis.. *International Journal of Cardiology*, **2022**,	3.2	1
295	Sudden cardiac death in cardiomyopathies: acting upon "acceptable" risk in the personalized medicine era.. *Heart Failure Reviews*, **2022**, 1	5	0
294	Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning.. *JMIR Medical Informatics*, **2022**, 10, e30483	3.6	2
293	The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2022**, 18, 1-8	3.3	0
292	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. *Heart*, **2022**, 108, 54-60	5.1	1
291	Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 851905	5.4	0
290	Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different Mutations.. *Frontiers in Physiology*, **2022**, 13, 864547	4.6	0
289	Sex-Related Differences in Genetic Cardiomyopathies.. *Journal of the American Heart Association*, **2022**, e024947	6	1
288	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy.. *Circulation: Arrhythmia and Electrophysiology*, **2022**, CIRCEP121010075	6.4	0
287	Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy.. *Journal of the American College of Cardiology*, **2022**, 79, 1986-1997	15.1	1
286	Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *European Journal of Neurology*, **2021**, 28, 3809-3813	6	2
285	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003062	5.2	10
284	Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study. *Journal of Cardiovascular Medicine*, **2021**, 22, 511-513	1.9	1
283	Prevalence of Inherited Cardiac Diseases Among Young Patients Requiring Permanent Pacing. *Circulation: Arrhythmia and Electrophysiology*, **2021**, CIRCEP121010562	6.4	0
282	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	5
281	Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy. *Kardiologia Polska*, **2021**, 79, 949-954	0.9	1
280	Neither Athletic Training nor Detraining Affects LV Hypertrophy in Adult, Low-Risk Patients With HCM. *JACC: Cardiovascular Imaging*, **2021**, 15, 170-170	8.4	0

279	Creatine deficiency and heart failure. *Heart Failure Reviews*, **2021**, 1	5	1
278	Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy. *Journal of the American Heart Association*, **2021**, 10, e021141	6	1
277	Sport practice in hypertrophic cardiomyopathy: running to stand still?. *International Journal of Cardiology*, **2021**, 345, 77-82	3.2	1
276	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. *Journal of Clinical Medicine*, **2021**, 10,	5.1	4
275	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 1988-1996	9.5	20
274	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	9
273	Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
272	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. *Genetics in Medicine*, **2021**, 23, 1281-1287	8.1	3
271	Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities?. *British Journal of Haematology*, **2021**, 193, e27-e31	4.5	0
270	Is heart failure with preserved ejection fraction a 'dementia' of the heart?. *Heart Failure Reviews*, **2021**, 1	5	1
269	Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. *Heart Failure Clinics*, **2021**, 17, 303-313	3.3	4
268	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). *European Respiratory Journal*, **2021**, 57,	13.6	7
267	Endocarditis with spondylodiscitis: clinical characteristics and prognosis. *BMC Cardiovascular Disorders*, **2021**, 21, 186	2.3	1
266	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2021**, 397, 2467-2475	40	19
265	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. *Current Cardiology Reports*, **2021**, 23, 79	4.2	5
264	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. *Current Heart Failure Reports*, **2021**, 18, 169-179	2.8	2
263	Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care. *JACC: Cardiovascular Imaging*, **2021**, 14, 2123-2134	8.4	2
262	Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening. *Journal of Cardiovascular Medicine*, **2021**, 22, 759-766	1.9	

261	Arrhythmogenic potential of myocardial disarray in hypertrophic cardiomyopathy: genetic basis, functional consequences and relation to sudden cardiac death. *Europace*, **2021**, 23, 985-995	3.9	2
260	A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains. *Computers in Biology and Medicine*, **2021**, 134, 104520	7	3
259	Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy. *Clinical and Translational Medicine*, **2021**, 11, e435	5.7	0
258	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. *Genetics in Medicine*, **2021**, 23, 69-79	8.1	4
257	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. *ESC Heart Failure*, **2021**, 8, 95-105	3.7	4
256	Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients. *European Heart Journal Digital Health*, **2021**, 2, 175-178	2.3	2
255	Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes. *Journal of Cardiovascular Electrophysiology*, **2021**, 32, 657-666	2.7	3
254	Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre. *BMC Cardiovascular Disorders*, **2021**, 21, 28	2.3	5
253	The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era. *European Journal of Heart Failure*, **2021**, 23, 1062-1067	12.3	0
252	Mavacamten for hypertrophic obstructive cardiomyopathy - Authors' reply. *Lancet, The*, **2021**, 397, 369-370	40	0
251	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1488-1490	4.5	1
250	Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center. *Open Forum Infectious Diseases*, **2021**, 8, ofab049	1	4
249	Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2021**, 77, 922-936	15.1	26
248	Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2021**, 28, 211-212	2.7	2
247	Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning: Management With VA-ECMO and Myectomy. *JACC: Case Reports*, **2021**, 3, 433-437	1.2	1
246	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre. *European Journal of Internal Medicine*, **2021**, 85, 68-79	3.9	5
245	Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. *International Journal of Cardiology*, **2021**, 335, 123-127	3.2	4
244	Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 1544-1549	13.4	7

243	Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability. *Journal of the American Medical Directors Association*, **2021**, 22, 1588-1592.e1	5.9	6
242	Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. *Mayo Clinic Proceedings*, **2021**, 96, 2185-2191	6.4	2
241	A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy. *Computers in Biology and Medicine*, **2021**, 135, 104648	7	5
240	Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
239	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. *European Journal of Preventive Cardiology*, **2021**,	3.9	6
238	Recognition of pre-hypertrophic cardiac involvement in Fabry Disease based on automated electrocardiographic measures. *International Journal of Cardiology*, **2021**, 338, 121-126	3.2	0
237	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 3932-3944	9.5	6
236	Sex-related differences in ventricular remodeling after myocardial infarction. *International Journal of Cardiology*, **2021**, 339, 62-69	3.2	1
235	Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. *ESC Heart Failure*, **2021**,	3.7	4
234	Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies. *Genetics in Medicine*, **2021**, 23, 856-864	8.1	12
233	Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study.. *European Journal of Internal Medicine*, **2021**,	3.9	10
232	Variational Gaussian Mixture Models with robust Dirichlet concentration priors for virtual population generation in hypertrophic cardiomyopathy: a comparison study. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2021**, 2021, 1674-1677	0.9	0
231	Racial Differences in Val122Ile associated Transthyretin Cardiac Amyloidosis.. *Journal of Cardiac Failure*, **2021**,	3.3	1
230	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.. *Journal of the American College of Cardiology*, **2021**, 78, 2518-2532	15.1	7
229	A rare case of pediatric cardiomyopathy: Alstrm syndrome identified by gene panel analysis. *Clinical Case Reports (discontinued)*, **2020**, 8, 3369-3373	0.7	0
228	Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. *BMC Cardiovascular Disorders*, **2020**, 20, 516	2.3	8
227	Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. *Circulation Genomic and Precision Medicine*, **2020**, 13, e003117	5.2	10
226	Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. *Cardiovascular Research*, **2020**, 116, 1585-1599	9.9	16

225	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. *Circulation*, **2020**, 142, 217-229	16.7	51
224	Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy. *Frontiers in Physiology*, **2020**, 11, 368	4.6	4
223	Antiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditis. *Rheumatology*, **2020**, 59, e88-e90	3.9	3
222	Mitochondrial Energetics and Ca2-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
221	Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2020**, 13, e006853	7.6	21
220	Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy. *JACC: Cardiovascular Imaging*, **2020**, 13, 2262-2264	8.4	5
219	The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. *European Journal of Internal Medicine*, **2020**, 77, 163-164	3.9	1
218	Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: Ready for prime time. *European Journal of Preventive Cardiology*, **2020**, 2047487320928654	3.9	5
217	Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. *Circulation: Heart Failure*, **2020**, 13, e006619	7.6	9
216	Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. *Clinical Cardiology*, **2020**, 43, 430-440	3.3	4
215	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. *European Journal of Heart Failure*, **2020**, 22, 1076-1096	12.3	33
214	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. *Journal of the American College of Cardiology*, **2020**, 76, 186-197	15.1	16
213	Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy. *Cardiovascular Drugs and Therapy*, **2020**, 34, 241-253	3.9	13
212	Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study. *Heart Rhythm*, **2020**, 17, 1107-1114	6.7	11
211	Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy. *Circulation*, **2020**, 141, 387-398	16.7	71
210	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. *Circulation*, **2020**, 141, 828-842	16.7	66
209	Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. *European Journal of Internal Medicine*, **2020**, 78, 82-87	3.9	2
208	The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. *European Journal of Heart Failure*, **2020**, 22, 1097-1107	12.3	18

207	Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?. *Journal of the American Heart Association*, **2020**, 9, e015473	6	15
206	On the Cardiac Loop and Its Failing: Left Ventricular Outflow Tract Obstruction. *Journal of the American Heart Association*, **2020**, 9, e014857	6	3
205	Epidemiology of cardiomyopathies: essential context knowledge for a tailored clinical work-up. *European Journal of Preventive Cardiology*, **2020**,	3.9	1
204	Targeted Medical Therapies for Hypertrophic Cardiomyopathy. *Current Cardiology Reports*, **2020**, 22, 10	4.2	6
203	Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2020**, 5, 65-72	16.2	29
202	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2020**, 27, 1821-1831	3.9	5
201	Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. *International Journal of Cardiology*, **2020**, 304, 86-92	3.2	9
200	IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE. *Retina*, **2020**, 40, 1623-1629	3.6	3
199	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2020**, 5, 83-91	16.2	23
198	Generation of virtual patient data for in-silico cardiomyopathies drug development using tree ensembles: a comparative study. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2020**, 2020, 5343-5346	0.9	0
197	Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates. *IJC Heart and Vasculature*, **2020**, 31, 100633	2.4	2
196	Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders. *Orphanet Journal of Rare Diseases*, **2020**, 15, 196	4.2	5
195	Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations. *PLoS ONE*, **2020**, 15, e0236814	3.7	1
194	Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2020**, 318, 94-100	3.2	2
193	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. *Molecular Genetics and Metabolism*, **2020**, 131, 219-228	3.7	13
192	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry. *Circulation: Heart Failure*, **2020**, 13, e007230	7.6	16
191	Spatial and Functional Distribution of Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, 396-405	5.2	19
190	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2020**, 396, 759-769	40	149

189	The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. *Heart Rhythm*, **2020**, 17, 142-151	6.7	21
188	Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2020**, 300, 191-195	3.2	27
187	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. *Circulation*, **2020**, 141, 1371-1383	16.7	43
186	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. *Genome Medicine*, **2019**, 11, 5	14.4	54
185	Performance of the CHADS-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. *European Journal of Internal Medicine*, **2019**, 62, 24-28	3.9	8
184	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. *Circulation*, **2019**, 139, 830-833	16.7	25
183	Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". *Circulation*, **2019**, 139, 1559-1560	16.7	2
182	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. *American Heart Journal*, **2019**, 214, 28-35	4.9	1
181	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2019**, 291, 77-82	3.2	12
180	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. *Genetics in Medicine*, **2019**, 21, 284-292	8.1	32
179	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). *JAMA Cardiology*, **2019**, 4, 918-927	16.2	67
178	The spectrum of myocarditis: from pathology to the clinics. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 279-301	5.1	42
177	Heritability in genetic heart disease: the role of genetic background. *Open Heart*, **2019**, 6, e000929	3	7
176	Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. *JACC Basic To Translational Science*, **2019**, 4, 795-813	8.7	13
175	Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. *Journal of the American College of Cardiology*, **2019**, 74, 2333-2345	15.1	60
174	Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised, Home-Based Physical Activity Intervention for Chronic Heart Failure (Active-at-Home-HF): a Pilot Study. *Sports Medicine - Open*, **2019**, 5, 45	6.1	5
173	Comment on: Assessment of cardiac disease in MELAS requires comprehensive, prospective work-up. *International Journal of Cardiology*, **2019**, 280, 162	3.2	
172	Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). *European Heart Journal*, **2019**, 40, 19-33	9.5	174

171	Clinical profile and outcome of cardiac involvement in MELAS syndrome. *International Journal of Cardiology*, **2019**, 276, 14-19	3.2	8
170	Letter regarding the article 'Heart failure with preserved ejection fraction: from mechanisms to therapies' by Lam and colleagues. *European Heart Journal*, **2019**, 40, 703-704	9.5	3
169	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. *JAMA Cardiology*, **2018**, 3, 520-525	16.2	52
168	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. *Circulation: Arrhythmia and Electrophysiology*, **2018**, 11, e005820	6.4	26
167	Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. *British Journal of Pharmacology*, **2018**, 175, 2635-2652	8.6	31
166	Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria. *Journal of the American College of Cardiology*, **2018**, 71, 464-466	15.1	15
165	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. *Revista Portuguesa De Cardiologia*, **2018**, 37, 1-10	1	25
164	Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. *Circulation: Heart Failure*, **2018**, 11, e004124	7.6	56
163	Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. *European Heart Journal Cardiovascular Imaging*, **2018**, 19, 601-610	4.1	23
162	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. *Revista Portuguesa De Cardiologia (English Edition)*, **2018**, 37, 1-10	0	13
161	Clinical and Molecular Aspects of Cardiomyopathies: Emerging Therapies and Clinical Trials. *Heart Failure Clinics*, **2018**, 14, 161-178	3.3	3
160	Common presentation of rare cardiac diseases: Arrhythmias. *International Journal of Cardiology*, **2018**, 257, 351-357	3.2	1
159	Channelopathies, cardiac hypertrophy, and the theory of light. *European Heart Journal*, **2018**, 39, 2908-2910	9.5	4
158	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). *Circulation*, **2018**, 137, 1015-1023	16.7	95
157	Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications. *Journal of Cardiovascular Medicine*, **2018**, 19, 1-11	1.9	33
156	Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. *European Journal of Heart Failure*, **2018**, 20, 898-906	12.3	34
155	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). *Circulation*, **2018**, 138, 1387-1398	16.7	210
154	Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management. *Progress in Pediatric Cardiology*, **2018**, 51, 24-30	0.4	1

153	Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2018**, 273, 155-161	3.2	10
152	Cardiomyopathies in children Inherited heart muscle disease: Overview of hypertrophic, dilated, restrictive and non-compaction phenotypes. *Progress in Pediatric Cardiology*, **2018**, 51, 8-15	0.4	1
151	Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2018**, 11, e005191	7.6	21
150	Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study. *Journal of Biomolecular Structure and Dynamics*, **2017**, 35, 1916-1922	3.6	13
149	Determinants of discrepancies between two-dimensional echocardiographic methods for assessment of maximal left atrial volume. *European Heart Journal Cardiovascular Imaging*, **2017**, 18, 584-602	4.1	4
148	Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. *Cardiovascular Ultrasound*, **2017**, 15, 3	2.4	59
147	Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2017**, 231, 115-119	3.2	21
146	Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2017**, 10,	3.9	19
145	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. *Journal of Medical Genetics*, **2017**, 54, 288-296	5.8	193
144	Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2017**, 10,	7.6	55
143	Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart). *International Journal of Cardiology*, **2017**, 236, 249-252	3.2	12
142	Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a NH gated PET study. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 866-875	8.8	20
141	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. *Circulation: Cardiovascular Genetics*, **2017**, 10,		27
140	B-lines with Lung Ultrasound: The Optimal Scan Technique at Rest and During Stress. *Ultrasound in Medicine and Biology*, **2017**, 43, 2558-2566	3.5	32
139	Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?. *International Journal of Cardiology*, **2017**, 246, 55	3.2	
138	Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models. *Journal of the American Heart Association*, **2017**, 6,	6	32
137	Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. *JAMA Cardiology*, **2017**, 2, 1153-1160	16.2	45
136	Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy. *JAMA Cardiology*, **2017**, 2, 1147-1151	16.2	10

135	Role of Exercise Testing in Hypertrophic Cardiomyopathy. *JACC: Cardiovascular Imaging*, **2017**, 10, 1374-1386	8.4	39
134	Abrupt Onset of Refractory Heart Failure Associated With Light-Chain Amyloidosis in Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2017**, 2, 94-97	16.2	2
133	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. *Nature Reviews Cardiology*, **2017**, 14, 102-112	14.8	17
132	Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study. *International Journal of Cardiology*, **2017**, 227, 743-750	3.2	5
131	Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy. *Journal of the American Heart Association*, **2017**, 6,	6	20
130	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. *Heart Rhythm*, **2016**, 13, 457-63	6.7	36
129	Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 2413-2422	8.8	12
128	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts. *Circulation: Heart Failure*, **2016**, 9,	7.6	60
127	Electrophysiological correlates of word recognition memory process in patients with ischemic left ventricular dysfunction. *Clinical Neurophysiology*, **2016**, 127, 3007-3013	4.3	1
126	Multidimensional structure-function relationships in human cardiac myosin from population-scale genetic variation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 6701-6	11.5	68
125	Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: The International Stress Echo Registry. *International Journal of Cardiology*, **2016**, 219, 331-8	3.2	22
124	Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. *Journal of the American College of Cardiology*, **2016**, 67, 1399-1409	15.1	101
123	Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. *American Journal of Cardiology*, **2016**, 117, 1651-1654	3	43
122	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2016**, 117, 1151-9	3	16
121	Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial. *Circulation: Heart Failure*, **2016**, 9, e002764	7.6	30
120	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2016**, 118, 432-9	3	27
119	Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal. *Heart Rhythm*, **2016**, 13, 2395-2398	6.7	
118	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. *European Journal of Heart Failure*, **2016**, 18, 1106-18	12.3	64

117	An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2015**, 8, 232-43	2.3	14
116	Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2015**, 116, 436-41	3	51
115	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2015**, 8, 1014-21	7.6	44
114	Validation of pixel-wise parametric mapping of myocardial blood flow with □□NH□PET in patients with hypertrophic cardiomyopathy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2015**, 42, 1581-8	8.8	7
113	Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas: an emerging problem in Europe. *Journal of Cardiovascular Medicine*, **2015**, 16, 817-23	1.9	11
112	Left Ventricular Apex Involvement in Hypertrophic Cardiomyopathy. *Echocardiography*, **2015**, 32, 1575-80	1.5	3
111	Research priorities in sarcomeric cardiomyopathies. *Cardiovascular Research*, **2015**, 105, 449-56	9.9	41
110	Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?. *Global Cardiology Science & Practice*, **2015**, 2015, 16	0.7	9
109	INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy-a Randomised Intervention Trial with losartan). *Global Cardiology Science & Practice*, **2015**, 2015, 7	0.7	6
108	Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. *Cardiovascular Research*, **2015**, 105, 409-23	9.9	46
107	Stress Echocardiography in Hypertrophic Cardiomyopathy **2015**, 551-568		
106	Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy. *Global Cardiology Science & Practice*, **2015**, 2015, 51	0.7	
105	MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. *Radiology*, **2014**, 273, 329-48	20.5	50
104	Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. *Circulation*, **2014**, 130, 484-95	16.7	554
103	Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. *Journal of the American College of Cardiology*, **2014**, 64, 83-99	15.1	407
102	Novel □actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. *Circulation: Cardiovascular Genetics*, **2014**, 7, 741-50		53
101	Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2014**, 114, 769-76	3	56
100	Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. *American Journal of Cardiology*, **2014**, 113, 1394-400	3	74

99	Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis. *International Journal of Cardiology*, **2014**, 172, e356-8	3.2	1
98	Reply: Obstructive sleep apnea and hypertrophic cardiomyopathy: obiter dictum or more?. *Journal of the American College of Cardiology*, **2014**, 64, 2562	15.1	1
97	Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. *Journal of the American College of Cardiology*, **2014**, 64, 2589-2600	15.1	69
96	Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization. *Journal of the American College of Cardiology*, **2013**, 62, 2010-9	15.1	120
95	Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. *International Journal of Cardiology*, **2013**, 167, 1038-45	3.2	25
94	Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. *International Journal of Cardiology*, **2013**, 168, e113-5	3.2	50
93	Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2013**, 112, 1190-6	3	25
92	Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. *Journal of Cardiovascular Translational Research*, **2013**, 6, 65-80	3.3	22
91	Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2013**, 62, 449-57	15.1	78
90	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management. *Circulation: Heart Failure*, **2013**, 6, 913-21	7.6	32
89	Response to letter regarding article, "Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy". *Circulation*, **2013**, 128, e157	16.7	7
88	Regulation of intracellular Na(+) in health and disease: pathophysiological mechanisms and implications for treatment. *Global Cardiology Science & Practice*, **2013**, 2013, 222-42	0.7	13
87	Hypertrophic cardiomyopathy: The need for randomized trials. *Global Cardiology Science & Practice*, **2013**, 2013, 243-8	0.7	7
86	Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. *Circulation*, **2013**, 127, 575-84	16.7	244
85	Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. *European Journal of Heart Failure*, **2013**, 15, 1363-73	12.3	37
84	Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. *PLoS ONE*, **2013**, 8, e59206	3.7	16
83	Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. *European Heart Journal*, **2012**, 33, 1724-33	9.5	115
82	The coronary circulation and blood flow in left ventricular hypertrophy. *Journal of Molecular and Cellular Cardiology*, **2012**, 52, 857-64	5.8	117

81	Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2012**, 110, 715-9	3	46
80	Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care. *American Journal of Cardiology*, **2012**, 109, 718-23	3	34
79	Dynamic assessment of 'valvular reserve capacity' in patients with rheumatic mitral stenosis. *European Heart Journal Cardiovascular Imaging*, **2012**, 13, 476-82	4.1	30
78	Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. *Circulation: Heart Failure*, **2012**, 5, 535-46	7.6	165
77	Clinical and molecular classification of cardiomyopathies. *Global Cardiology Science & Practice*, **2012**, 2012, 4	0.7	12
76	Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. *Global Cardiology Science & Practice*, **2012**, 2012, 9	0.7	8
75	Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. *BMJ Open*, **2012**, 2,	3	12
74	Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. *Journal of the American College of Cardiology*, **2011**, 58, 839-48	15.1	101
73	Genetic testing for hypertrophic cardiomyopathy: ongoing voyage from exploration to clinical exploitation. *Neurology International*, **2011**, 1, 3	0	
72	Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. *Circulation*, **2011**, 124, 40-7	16.7	251
71	Determinants of echocardiographic left atrial volume: implications for normalcy. *European Journal of Echocardiography*, **2011**, 12, 826-33		49
70	Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. *European Heart Journal*, **2011**, 32, 1114-20	9.5	70
69	Distal extremity pain as a presenting feature of Fabry's disease. *Arthritis Care and Research*, **2011**, 63, 390-5	4.7	9
68	Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. *Europace*, **2010**, 12, 347-55	3.9	111
67	Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. *Journal of the American College of Cardiology*, **2010**, 55, 1444-53	15.1	207
66	Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy. *Journal of Thoracic and Cardiovascular Surgery*, **2010**, 140, 1046-52	1.5	12
65	Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *American Journal of Cardiology* , **2010**, 106, 261-7	3	111
64	Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2010**, 106, 1301-6	3	31

63	Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. *Cardiovascular Ultrasound*, **2010**, 8, 7	2.4	40
62	Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil. *European Heart Journal*, **2009**, 30, 1549-50	9.5	7
61	Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy. *Nature Clinical Practice Cardiovascular Medicine*, **2009**, 6, 134-9		5
60	Looking for hypertrophic cardiomyopathy in the community: why is it important?. *Journal of Cardiovascular Translational Research*, **2009**, 2, 392-7	3.3	4
59	The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice. *Journal of Cardiovascular Translational Research*, **2009**, 2, 349-67	3.3	46
58	Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2009**, 2, 452-61	3.3	39
57	The left ventricular outflow in hypertrophic cardiomyopathy: from structure to function. *Journal of Cardiovascular Translational Research*, **2009**, 2, 510-7	3.3	7
56	Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. *Journal of Nuclear Cardiology*, **2009**, 16, 92-6	2.1	20
55	The case for myocardial ischemia in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2009**, 54, 866-75	15.1	188
54	Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. *Journal of the American College of Cardiology*, **2009**, 54, 220-8	15.1	304
53	Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. *Nature Reviews Cardiology*, **2009**, 6, 317-21	14.8	55
52	The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. *Journal of Physiology*, **2008**, 586, 3639-44	3.9	81
51	Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2008**, 52, 559-66	15.1	205
50	Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. *Mayo Clinic Proceedings*, **2008**, 83, 630-8	6.4	132
49	Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. *Journal of Nuclear Medicine*, **2008**, 49, 1090-6	8.9	58
48	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. *Mayo Clinic Proceedings*, **2008**, 83, 630-638	6.4	261
47	Left ventricular apical ballooning syndrome as a novel cause of acute mitral regurgitation. *Journal of the American College of Cardiology*, **2007**, 50, 647-9	15.1	84
46	Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial?. *Journal of the American College of Cardiology*, **2007**, 50, 831-4	15.1	87

45	Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2007**, 99, 1575-81	3	66
44	ECG-based screening: not only for athletes. *European Heart Journal*, **2007**, 28, 1170	9.5	2
43	'End-stage' hypertrophic cardiomyopathy: from mystery to model. *Nature Clinical Practice Cardiovascular Medicine*, **2007**, 4, 232-3		27
42	Response to Letter Regarding Article, Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction *Circulation*, **2007**, 115,	16.7	1
41	Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. *International Journal of Cardiology*, **2007**, 114, 57-63	3.2	15
40	Hypertrophic Cardiomyopathy in Anderson-Fabry Disease. *Clinical Therapeutics*, **2007**, 29, S93-S94	3.5	1
39	Midventricular obstruction and clinical decision-making in obstructive hypertrophic cardiomyopathy. *Herz*, **2006**, 31, 871-6	2.6	14
38	Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. *American Journal of Cardiology*, **2006**, 97, 1386-90	3	115
37	Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). *American Journal of Cardiology*, **2006**, 98, 960-5	3	160
36	The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators?. *European Heart Journal*, **2006**, 27, 1895-7	9.5	18
35	Minimally Invasive and Noninvasive Hemodynamic Monitoring of the Cardiovascular System: Available Options and Future Perspectives. *Current Cardiology Reviews*, **2006**, 2, 37-39	2.4	11
34	Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2006**, 47, 1043-8	15.1	169
33	Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. *Circulation*, **2006**, 114, 2232-9	16.7	614
32	Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. *American Heart Journal*, **2006**, 151, 1094-1100	4.9	20
31	Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. *Archives of Internal Medicine*, **2006**, 166, 2151-6		72
30	A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. *Journal of Cardiovascular Medicine*, **2006**, 7, 601-7	1.9	52
29	The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. *American Heart Journal*, **2005**, 150, 947-54	4.9	47
28	Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2005**, 46, 470-6	15.1	514

27	Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2005**, 46, 480-7	15.1	262
26	Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. *European Journal of Heart Failure*, **2005**, 7, 566-71	12.3	34
25	Hypertrophic cardiomyopathy in the community: why we should care. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 324-5		11
24	Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2004**, 5, 572-80		6
23	Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2003**, 349, 1027-35	59.2	552
22	Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence). *European Heart Journal*, **2003**, 24, 1195-203	9.5	40
21	Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. *American Journal of Cardiology*, **2003**, 92, 1358-62	3	34
20	Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2003**, 41, 315-21	15.1	111
19	Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *New England Journal of Medicine*, **2003**, 348, 295-303	59.2	928
18	The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. *Italian Heart Journal: Official Journal of the Italian Federation of Cardiology*, **2003**, 4, 596-601		2
17	New concepts in hypertrophic cardiomyopathies. *Circulation*, **2002**, 105, e188; author reply e188	16.7	1
16	Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2002**, 39, 301-7	15.1	261
15	Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area. *American Heart Journal*, **2002**, 144, 630-5	4.9	7
14	Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. *Current Cardiology Reports*, **2001**, 3, 141-6	4.2	22
13	Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. *Circulation*, **2001**, 104, 2517-24	16.7	571
12	Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. *Circulation*, **2000**, 101, 2817-22	16.7	648
11	Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. *Circulation*, **2000**, 102, 858-64	16.7	596
10	Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **1999**, 33, 2044-51	15.1	182

9	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. *American Journal of Cardiology*, **1998**, 82, 1230-5	3	84
8	Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. *American Heart Journal*, **1998**, 136, 972-81	4.9	58
7	Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. *European Heart Journal*, **1997**, 18, 1946-50	9.5	4
6	Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism. *American Journal of Cardiology*, **1996**, 77, 266-9	3	44
5	Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. *American Journal of Cardiology*, **1996**, 77, 1197-201	3	19
4	Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. *Journal of the American College of Cardiology*, **1995**, 26, 1529-36	15.1	218
3	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: The case of hypertrophic cardiomyopathy		1
2	The genetic architecture of left ventricular non-compaction reveals both substantial overlap with other cardiomyopathies and a distinct aetiology in a subset of cases		1
1	Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy105-120		3